Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants
LAGOS (Capital Markets in Africa) – Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing. This effort is part of the company’s ongoing program to develop a cocktail of antibodies targeting spike and non-spike proteins that can…
Read More